Biologics for Severe Asthma: A Growing Treatment Class

This CME-accredited four-part CME Snapshot™ series is intended for pulmonologists, allergists, and other specialists involved in the long-term care of patients with severe asthma. In this educational series, expert faculty will review clinical practice guidelines, discuss new approaches to therapy, and hear directly from patients with severe asthma.

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, allergists, and other specialists responsible for the long-term care of patients with severe asthma.

Educational Objectives

Upon completion of this activity, participants will be better able to do the following:

  1. Describe the mechanisms of action, published evidence, and prescribing considerations for biologic therapies in severe asthma

Faculty

Monica Kraft, MD
Chair, Department of Medicine
The Robert Irene Flinn Endowed Chair of Medicine
University of Arizona (UA) College of Medicine
Deputy Director
UA Health Sciences Asthma and Airway
Disease Research Center
Tucson, Arizona

Reynold A. Panettieri, Jr, MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Monica Kraft, MD

Grant/Research:Chiesi USA, Inc.; F. Hoffman-La Roche Ltd.; National Institutes of Health; sanofi-aventis U.S. LLC 

Consultant/Advisor: AstraZeneca; Teva Pharmaceutical Industries Ltd.

Royalties: Elsevier

Reynold A. Panettieri, Jr, MD

Speakers’ Bureau: AstraZeneca; Boehringer-Ingelheim; Boston Scientific Corporation; MedImmune, LLC; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.

Consultant/Advisor: AstraZeneca; MedImmune, LLC; Novartis Pharmaceuticals Corporation

Research Grant: Amgen Inc.; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.; Gilead Sciences, Inc.; MedImmune, LLC; Novartis Pharmaceuticals Corporation; OncoArendi Therapeutics SA; RFIM; sanofi-aventis U.S. LLC; Theratrophix, LLC; Vertex Pharmaceuticals Incorporated

Non-faculty: Rose O’Connor, PhD, CHCP; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from AstraZeneca.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications. 

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Integritas Communications, and AstraZeneca do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician
Course opens: 
12/19/2018
Course expires: 
12/18/2019
Rating: 
0

Available Credit

  • 0.25 AMA PRA Category 1 Credit(s)™
  • 0.25 Non-physician

Accreditation Period

Course opens: 
12/19/2018
Course expires: 
12/18/2019
Please login or register to take this course.